CA3110817C - Application and uses of prg4 and therapeutic modulation thereof - Google Patents

Application and uses of prg4 and therapeutic modulation thereof Download PDF

Info

Publication number
CA3110817C
CA3110817C CA3110817A CA3110817A CA3110817C CA 3110817 C CA3110817 C CA 3110817C CA 3110817 A CA3110817 A CA 3110817A CA 3110817 A CA3110817 A CA 3110817A CA 3110817 C CA3110817 C CA 3110817C
Authority
CA
Canada
Prior art keywords
prg4
composition
pharmaceutical composition
protein
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3110817A
Other languages
English (en)
French (fr)
Other versions
CA3110817A1 (en
Inventor
Benjamin Sullivan
Edward R. Truitt
Nicole Barbara Justis Truitt
David A. Sullivan
Tannin Schmidt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The Schepens Eye Research Institute Inc
Lubris LLC
Original Assignee
The Schepens Eye Research Institute Inc
Lubris LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Schepens Eye Research Institute Inc, Lubris LLC filed Critical The Schepens Eye Research Institute Inc
Publication of CA3110817A1 publication Critical patent/CA3110817A1/en
Application granted granted Critical
Publication of CA3110817C publication Critical patent/CA3110817C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0063—Periodont
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0041—Mammary glands, e.g. breasts, udder; Intramammary administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Birds (AREA)
  • Immunology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Physiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
CA3110817A 2009-05-22 2010-05-24 Application and uses of prg4 and therapeutic modulation thereof Active CA3110817C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18052509P 2009-05-22 2009-05-22
US61/180,525 2009-05-22
CA2762989A CA2762989C (en) 2009-05-22 2010-05-24 Prg4 for treatment of oral cavity boundary lubrication disorders

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2762989A Division CA2762989C (en) 2009-05-22 2010-05-24 Prg4 for treatment of oral cavity boundary lubrication disorders

Publications (2)

Publication Number Publication Date
CA3110817A1 CA3110817A1 (en) 2010-11-25
CA3110817C true CA3110817C (en) 2023-08-15

Family

ID=43126811

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3110817A Active CA3110817C (en) 2009-05-22 2010-05-24 Application and uses of prg4 and therapeutic modulation thereof
CA2762989A Active CA2762989C (en) 2009-05-22 2010-05-24 Prg4 for treatment of oral cavity boundary lubrication disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2762989A Active CA2762989C (en) 2009-05-22 2010-05-24 Prg4 for treatment of oral cavity boundary lubrication disorders

Country Status (7)

Country Link
US (2) US9730865B2 (cg-RX-API-DMAC10.html)
EP (1) EP2432492B1 (cg-RX-API-DMAC10.html)
JP (4) JP2012527485A (cg-RX-API-DMAC10.html)
CN (1) CN102711796A (cg-RX-API-DMAC10.html)
CA (2) CA3110817C (cg-RX-API-DMAC10.html)
ES (1) ES2532526T3 (cg-RX-API-DMAC10.html)
WO (1) WO2010135736A2 (cg-RX-API-DMAC10.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010135736A2 (en) 2009-05-22 2010-11-25 Singularis Inc. Application and uses of prg4 and therapeutic modulation thereof
WO2011091000A2 (en) * 2010-01-19 2011-07-28 Singularis, Inc. Oral care compositions and methods
WO2014115022A1 (en) * 2013-01-25 2014-07-31 Baylor College Of Medicine A helper-dependent adenoviral gene therapy delivery and expression system
US9982027B2 (en) 2013-10-22 2018-05-29 Lubris Llc Control of rheological properties of mixed hyaluronate/lubricin solutions
US20150141328A1 (en) * 2013-11-18 2015-05-21 The Schepens Eye Research Institute Stimulation of human meibomian gland function
US10500250B2 (en) 2013-11-26 2019-12-10 Lubris Llc Compositions and methods for inhibiting intercellular interactions
EP2896429B1 (en) 2014-01-20 2018-07-18 COR S.a.r.l. Skin Protector
AU2016211694B2 (en) * 2015-01-26 2021-11-11 Lubris Llc Use of PRG4 as an anti-inflammatory agent
LT3300482T (lt) * 2015-05-19 2021-10-25 Lubris Llc Prg4 panaudojimas dinaminio regos aštrumo pagerinimui ir aukštesnės eilės aberacijų sumažinimui
US10695292B2 (en) 2015-06-23 2020-06-30 Fertin Pharma A/S Chewing gum composition for use in alleviation of xerostomia induced by radiotherapy treatment
CN105055949A (zh) * 2015-08-10 2015-11-18 孙霞 一种治疗小儿口腔溃疡的中药
CN108157358A (zh) * 2018-03-02 2018-06-15 沈阳汇翼宁消毒科技有限公司 一种消毒液及其制备方法
WO2019246522A1 (en) * 2018-06-21 2019-12-26 Lubris Llc Lubricin for use in wound healing
US20220008518A1 (en) * 2018-11-08 2022-01-13 The Schepens Eye Research Institute, Inc. Therapeutic approaches for tissue reconstruction and wound healing treatment
US12390488B2 (en) 2018-12-29 2025-08-19 Solventum Intellectual Properties Company Oral articles and methods of use
US12558305B2 (en) 2018-12-29 2026-02-24 Solventum Intellectual Properties Company Oral articles and methods of use
EP3982912A1 (en) 2019-06-14 2022-04-20 The Procter & Gamble Company Leave-on oral care compositions
EP3982913A1 (en) * 2019-06-14 2022-04-20 The Procter & Gamble Company Leave-on oral care compositions
WO2020248232A1 (en) * 2019-06-14 2020-12-17 The Procter & Gamble Company Leave-on oral care compositions
CN113950319A (zh) 2019-06-14 2022-01-18 宝洁公司 免洗型口腔护理组合物
WO2020248239A1 (en) * 2019-06-14 2020-12-17 The Procter & Gamble Company Leave-on oral care compositions
JP7272214B2 (ja) * 2019-09-24 2023-05-12 日油株式会社 デンタルプラーク・ステイン付着防止剤および口腔用組成物
CN111944595B (zh) * 2020-08-21 2022-08-09 健尔康医疗科技股份有限公司 一种医用外科器械用润滑剂及其制备和使用方法
CN121942025A (zh) * 2023-10-10 2026-04-28 华迎生物医学有限公司 循环液以及润滑性调整剂

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4438100A (en) * 1980-04-25 1984-03-20 A/S Orthana Kemisk Fabrik Sterilized preserved, stable mucine-containing solutions
US4938963A (en) * 1988-11-22 1990-07-03 Parnell Pharmaceuticals, Inc. Method and composition for treating xerostomia
US5326558A (en) 1989-08-08 1994-07-05 Genetics Institute, Inc. Megakaryocytopoietic factor
US6433142B1 (en) 1989-08-08 2002-08-13 Genetics Institute, Llc Megakaryocyte stimulating factors
US7001881B1 (en) 1999-04-23 2006-02-21 Rhode Island Hospital Tribonectins
US6743774B1 (en) 1999-04-23 2004-06-01 Rhode Island Hospital Tribonectins
US6960562B2 (en) 1999-04-23 2005-11-01 Rhode Island Hospital, A Lifespan Partner Tribonectin polypeptides and uses thereof
GB2361870A (en) * 2000-05-03 2001-11-07 Zia Hashmi Treating xerostomia
EP1347993A2 (en) * 2000-12-29 2003-10-01 Glaxo Group Limited Superficial zone protein and methods of making and using same
US7071228B2 (en) * 2002-10-23 2006-07-04 Parks L Dean Method of treating musculoskeletal and connective tissue inflammations
US7415381B2 (en) 2003-01-09 2008-08-19 Rhode Island Hospital, A Lifespan Partner Joint friction sensing
RO120171B1 (ro) * 2003-05-23 2005-10-28 Ioan Nedelcu Produse cosmetice şi pentru igienă, procedeu de obţinere şi procedeu de aplicare a acestora
US20060240037A1 (en) 2003-06-04 2006-10-26 Edward Fey Methods and compositions for the treatment and prevention of degenerative joint disorders
WO2005016130A2 (en) * 2003-08-14 2005-02-24 Wyeth Recombinant lubricin molecules and uses thereof
CA2558497A1 (en) * 2004-03-05 2005-09-15 Synthes (U.S.A.) Use of a mixture for the production of an agent for treating defective or degenerated cartilage in the production of natural cartilage replacement in vitro
US8034796B2 (en) * 2004-04-07 2011-10-11 The University Of Georgia Research Foundation, Inc. Glucosamine and glucosamine/anti-inflammatory mutual prodrugs, compositions, and methods
WO2005102363A2 (en) 2004-04-20 2005-11-03 Mucosal Therapeutics Llc Methods of promoting cartilage healing or cartilage integration
US20080287369A1 (en) 2004-07-23 2008-11-20 Jay Gregory D Compositions and Methods for Viscosupplementation
ES2344911T3 (es) * 2004-08-02 2010-09-09 Glaxo Group Limited Composicion novedosa para tratar la xerostomia.
EP1827478A4 (en) * 2004-12-03 2009-08-05 Mucosal Therapeutics Llc METHODS OF TREATING JOINED OR SICK JOINTS
US20070111327A1 (en) 2005-05-05 2007-05-17 Jay Gregory D Methods of detecting lubricin
US8057458B2 (en) 2006-10-30 2011-11-15 Warsaw Orthopedic, Inc. Method for treating facet pain
US20090068247A1 (en) 2007-09-12 2009-03-12 Mucosal Therapeutics Biocompatible devices coated with a tribonectin and methods for their production
US20090104148A1 (en) 2007-09-18 2009-04-23 Jay Gregory D Treatment and prevention of joint disease
HRP20150097T1 (hr) 2008-05-07 2015-03-27 The Regents Of The University Of California Terapijska nadopuna i poboljšanje vlaženja površine oka
US8506944B2 (en) 2008-05-07 2013-08-13 The Regents Of The University Of California Replenishment and enrichment of ocular surface lubrication
EP2368076A1 (en) * 2008-12-19 2011-09-28 Kautex Textron CVS Limited Vehicular fluid heater
ES2534082T3 (es) 2009-01-13 2015-04-17 Lubris Llc Modulación terapéutica de la lubricación del límite del epitelio vaginal
WO2010135736A2 (en) 2009-05-22 2010-11-25 Singularis Inc. Application and uses of prg4 and therapeutic modulation thereof
CA2771110C (en) 2009-08-13 2019-02-26 Singularis, Inc. Prg4 treatment for interstitial cystitis
WO2011091000A2 (en) 2010-01-19 2011-07-28 Singularis, Inc. Oral care compositions and methods
US20130116186A1 (en) 2011-10-04 2013-05-09 Rhode Island Hospital, A Lifespan Partner Lubricin injections to maintain cartilage health
US9982027B2 (en) 2013-10-22 2018-05-29 Lubris Llc Control of rheological properties of mixed hyaluronate/lubricin solutions

Also Published As

Publication number Publication date
ES2532526T3 (es) 2015-03-27
EP2432492A2 (en) 2012-03-28
WO2010135736A2 (en) 2010-11-25
CA2762989A1 (en) 2010-11-25
CA2762989C (en) 2021-04-13
CA3110817A1 (en) 2010-11-25
US20180153776A1 (en) 2018-06-07
JP2015129115A (ja) 2015-07-16
WO2010135736A3 (en) 2011-04-28
JP2017105790A (ja) 2017-06-15
US9730865B2 (en) 2017-08-15
CN102711796A (zh) 2012-10-03
US20120134925A1 (en) 2012-05-31
JP2019048824A (ja) 2019-03-28
EP2432492B1 (en) 2014-12-24
JP6483164B2 (ja) 2019-03-13
US10383796B2 (en) 2019-08-20
JP2012527485A (ja) 2012-11-08
JP6159704B2 (ja) 2017-07-05
EP2432492A4 (en) 2013-07-31

Similar Documents

Publication Publication Date Title
US10383796B2 (en) Application and uses of PRG4 and therapeutic modulation thereof
EP2063859B1 (en) Cosmetic composition for the treatment of skin and methods thereof
CN104666112B (zh) 一种生物活性透明质酸牙膏
JPH11514967A (ja) 粘膜炎症の治療用医薬の製造のためのヒアルロン酸およびｎｓａｉｄの使用
US20240358743A1 (en) Cosmetic/dermatological composition
EA010945B1 (ru) Применение биосовместимого полимера для изготовления медицинского устройства
JP6256770B2 (ja) 口腔ケア組成物、錠剤、顆粒状薬剤
EP3290041B1 (en) Oral care composition
CN107446018A (zh) 促进伤口愈合的肽及其应用
JP6522286B2 (ja) ヒアルロン酸産生促進剤
TWI576117B (zh) 玻尿酸產生促進劑
WO2016174861A1 (ja) 口腔ケア組成物
EA048438B1 (ru) Применение фармацевтической композиции для лечения заболеваний и/или патологий тканей
HK1251470B (en) Oral care composition
HK1131553B (en) Cosmetic composition for the treatment of skin and methods thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210301